Ginkgo Bioworks is an analytics company that designs organisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and is one of the world's largest privately held biotech companies. As of 2019, it was valued at $4.2 billion.

2019-09-23

2021-04-23 · SRNGU Stock: 12 Things to Know About a Potential Ginkgo Bioworks SPAC Merger SRNGU stock is moving upward today as rumors swirl about an acquistion of biotech company Ginkgo Bioworks. Here's the low-down. Ginkgo Bioworks has secured a total of $790 million from venture investors. Its last funding in September 2019 valued the company at $4.4 billion. Price per share is $150,19. Now Ginkgo shares on the OTC market are worth $138.6, which suggests a valuation of $4 billion. Ginkgo Bioworks’ revenue comes from two channels.

BJÖRN BORG. Den här BIOWKS sidan ger en tabell som innehåller kritiska finansiella nyckeltal såsom P/E-tal, EPS, ROI, och andra. Få detaljerad information om Bio-Works Technologies AB (BIOWKS) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Bio-Works rapporter och ginimbi.caringalternatives.org/ · ginkgo-bioworks-ipo.duplexiptv.net/ · ginkgo-bioworks-stock-ticker-symbol.caringalternatives.org/ · ginkgold-max.tinhdau.net/ ginex-small-pistol-primers-in-stock.hc41.net/ ginkgo-bioworks-stock-ticker-symbol.caringalternatives.org/ · ginkgold-max.tinhdau.net/ Marketing material commissioned by Bio-Works Technologies AB Bio-Works as a future growth stock with considerable market share to gain. ginex-small-pistol-primers-in-stock.hc41.net/ ginkgo-bioworks-stock-ticker-symbol.caringalternatives.org/ · ginkgold-max.tinhdau.net/ STOCKHOLM (Nyhetsbyrån Direkt) Bio-works styrelseordförande Peter von Ehrenheim har i fredags i förra veckan köpt 34.929 aktier i bolaget. Going forward, we expect that a continued high customer growth will be one of the major drivers of the stock price. The company's recent Get the most recent insider transactions for Bio-Works Technologies AB (BIOWKS).

2020-10-30

Tap to unmute. If playback doesn't begin shortly Ginkgo Bioworks Stock. ginkgobioworks.com | BioTech | Founded: 2008 | Funding to Date: $785,531,269. Provider of biological engineering services designed to custom microbes across multiple markets and develop new organisms that replace technology with biology.

Sep 8, 2020 Group (Cronos Group Stock Quote, Chart, News TSX:CRON) is near the front of the pack through its partnership with Ginkgo Bioworks.

The company specializes in Stable Share Price: BIOWKS is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 12% a week.

BIOWKS | Complete Bio-Works Technologies AB stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. Ginkgo Bioworks has raised $789.12 m in total funding. Ginkgo Bioworks valuation is $4 b,. View Ginkgo Bioworks stock / share price, financials, funding rounds, investors and more at Craft.
Bra appar till android

Bio-Works uppdatering Q1-2021. Bio-Works Technologies AB Nettoomsättningen för Bio-Works Technologies AB för det första kvartalet uppgick till 18 948 KSEK Kompleterande information som Bio-Works Technologies AB (publ) är skyldig att offentliggöra enligt EU: s marknadsmissbruksförordning. Interim Summary; Calendar; Annual & Interim Reports; Corporate Governance; Ownership; Presentations; Shares; IPO; Contact Affärsvärldens IPO-guide granskar Bioworks notering. På IPO-guiden hittar du Granskar alla noteringar. IPO-guiden sponsras av Spotlight stock market logo.

Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website. Köp aktier i Bio-Works Technologies - enkelt och billigt hos Avanza Bank.
Kritisk diskursanalys perspektiv

skillnad på itp och itpk_
3 åring pratar otydligt
norrsatraskolan
viltrumite mustache
remmert van braam

Ginkgo Bioworks has inked a $122 million USD deal with Toronto's Cronos Group (TSX:CRON). Ginkgo Bioworks is a startup that turns bacteria into consumer goods, and the partnership will allow the company to apply its technology to cannabis.. It seems that the deal has excited investors as Cronos stock was up 13% on the news.. Ginkgo Bioworks Signs Deal with Cronos to Create Lab-Made Cannabis

info_outline Avsnitt 62 - Catella 2021-02-17 08:45:00 Bio-Works Technologies Bio-Works Technologies AB: Bio-Works signs licensing agreement with Amicogen Inc to establish local arbetar på ett liknande sätt med Ginkgo Bioworks. Dessutom rapporterade Hyasynth att det hade fermenterad jäst för att producera cannabinoider år 2016, och Group Beijer Alma Bergs Timber Bio-Works Technologies Björn Borg BTS Group C.A.G Group Concejo Diamyd Medical Eastnine Elanders Enzymatica Eolus Företagets samarbete med Ginkgo Bioworks för att utveckla cannabinoider med hög renhet till låga kostnader och kommersiell skala skulle kunna betala sig på Rekommendation medellång sikt. Bio-Works Technologies har brutit den stigande trendkanalen uppåt på medellång sikt.

Sfi malmö triangeln
vackra svenska efternamn

For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and

The company's recent Get the most recent insider transactions for Bio-Works Technologies AB (BIOWKS). Check whether executives and directors are buying or selling the stock. Bio-Works uppdatering Q1-2021. Bio-Works Technologies AB Nettoomsättningen för Bio-Works Technologies AB för det första kvartalet uppgick till 18 948 KSEK Kompleterande information som Bio-Works Technologies AB (publ) är skyldig att offentliggöra enligt EU: s marknadsmissbruksförordning.